Efficacy and Safety of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Low-dose Aspirin
Study Details
Study Description
Brief Summary
The purpose of this study is to evaluate the efficacy of TAK-438, once daily (QD) compared to AG-1749 (Lansoprazole) in patients with a history of gastric or duodenal ulcer who require long-term therapy of low-dose aspirin.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 3 |
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: TAK-438 10 mg QD
|
Drug: TAK-438
TAK-438 10 mg tablets, orally, once daily for up to 24 weeks.
Drug: Placebo
Lansoprazole placebo-matching capsules, orally, once daily for up to 24 weeks.
|
Experimental: TAK-438 20 mg QD
|
Drug: TAK-438
TAK-438 20 mg tablets, orally, once daily for up to 24 weeks.
Drug: Placebo
Lansoprazole placebo-matching capsules, orally, once daily for up to 24 weeks.
|
Active Comparator: Lansoprazole 15 mg QD
|
Drug: Lansoprazole
Lansoprazole 15 mg capsules, orally, once daily for up to 24 weeks.
Other Names:
Drug: Placebo
TAK-438 placebo-matching tablets, orally, once daily for up to 24 weeks.
|
Outcome Measures
Primary Outcome Measures
- Recurrence rate of gastric or duodenal ulcer within 24 weeks [24 weeks]
Mucosal defects with a white coating of 3 mm or larger will be determined as ulcers. Recurrence rate of gastric or duodenal ulcer within 24 weeks will be calculated for each treatment group.
Secondary Outcome Measures
- Recurrence rate of gastric or duodenal ulcer within 12 weeks [12 weeks]
- Gastric mucosal injury [24 Weeks]
- Duodenal mucosal injury [24 weeks]
- Occurrence rate of hemorrhagic lesion in stomach or duodenum [24 weeks]
- Time to recurrence of gastric or duodenal ulcer [24 weeks]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Participants who require continuous low-dose aspirin therapy during the treatment period with the study drug
-
Participants who have a history of ulcer in stomach or duodenum, endoscopically confirmed
-
Outpatient (including inpatient for examinations)
Exclusion Criteria:
-
Participants scheduled to change the type and dosage regimen of low-dose aspirin
-
Participants with ulcers or bleeding in stomach or duodenum, endoscopically confirmed
-
Participants with small intestine bleeding, large intestine bleeding, or gastrointestinal bleeding of unknown etiology
-
Participants who have a history of surgery which affects gastric acid secretion (e.g., resection of upper gastrointestinal tract, vagotomy) or who are scheduled to undergo such surgery
-
Participants with a previous or current history of Zollinger-Ellison syndrome, or other gastric acid hypersecretion disorders
-
Participants with a previous or current history of aspirin-induced asthma
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Komaki-shi | Aichi | Japan | ||
2 | Seto-shi | Aichi | Japan | ||
3 | Akita-shi | Akita | Japan | ||
4 | Ichikawa-shi | Chiba | Japan | ||
5 | Kisarazu-shi | Chiba | Japan | ||
6 | Matsudo-shi | Chiba | Japan | ||
7 | Imabari-shi | Ehime | Japan | ||
8 | Matsuyama-shi | Ehime | Japan | ||
9 | Niihama-shi | Ehime | Japan | ||
10 | Fukui-shi | Fukui | Japan | ||
11 | Chikushino-shi | Fukuoka | Japan | ||
12 | Fukuoka-shi | Fukuoka | Japan | ||
13 | Kasuya-gun | Fukuoka | Japan | ||
14 | Kitakyushu-shi | Fukuoka | Japan | ||
15 | Miyako-gun | Fukuoka | Japan | ||
16 | Onga-gun | Fukuoka | Japan | ||
17 | Yanagawa-shi | Fukuoka | Japan | ||
18 | Yukuhashi-shi | Fukuoka | Japan | ||
19 | Koriyama-shi | Fukushima | Japan | ||
20 | Gifu-shi | Gifu | Japan | ||
21 | Takasaki-shi | Gunma | Japan | ||
22 | Fukuyama-shi | Hiroshima | Japan | ||
23 | Hatsukaichi-shi | Hiroshima | Japan | ||
24 | Hiroshima-shi | Hiroshima | Japan | ||
25 | Asahikawa-shi | Hokkaido | Japan | ||
26 | Obihiro-shi | Hokkaido | Japan | ||
27 | Sapporo-shi | Hokkaido | Japan | ||
28 | Tomakomaki-shi | Hokkaido | Japan | ||
29 | Kobe-shi | Hyougo | Japan | ||
30 | Nishinomiya-shi | Hyougo | Japan | ||
31 | Takarazuka-shi | Hyougo | Japan | ||
32 | Koga-shi | Ibaragi | Japan | ||
33 | Tsuchiura-shi | Ibaragi | Japan | ||
34 | Kanazawa-shi | Ishikawa | Japan | ||
35 | Komatsu-shi | Ishikawa | Japan | ||
36 | Nomi-shi | Ishikawa | Japan | ||
37 | Shiroyama-shi | Ishikawa | Japan | ||
38 | Takamatsu-shi | Kagawa | Japan | ||
39 | Ibusuki-shi | Kagoshima | Japan | ||
40 | Ichikikushikino-shi | Kagoshima | Japan | ||
41 | Izumi-shi | Kagoshima | Japan | ||
42 | Atsugi-shi | Kanagawa | Japan | ||
43 | Kawasaki-shi | Kanagawa | Japan | ||
44 | Sagamihara-shi | Kanagawa | Japan | ||
45 | Yokohama-shi | Kanagawa | Japan | ||
46 | Kochi-shi | Kochi | Japan | ||
47 | Kumamoto-shi | Kumamoto | Japan | ||
48 | Kyoto-shi | Kyoto | Japan | ||
49 | Uji-shi | Kyoto | Japan | ||
50 | Tsu-shi | Mie | Japan | ||
51 | Sendai-shi | Miyagi | Japan | ||
52 | Nagasaki-shi | Nagasaki | Japan | ||
53 | Nara-shi | Nara | Japan | ||
54 | Niigata-shi | Niigata | Japan | ||
55 | Oita-shi | Oita | Japan | ||
56 | Osaka-shi | Osaka | Japan | ||
57 | Sakai-shi | Osaka | Japan | ||
58 | Tondabayashi-shi | Osaka | Japan | ||
59 | Ageo-shi | Saitama | Japan | ||
60 | Hiki-gun | Saitama | Japan | ||
61 | Kumagaya-shi | Saitama | Japan | ||
62 | Saitama-shi | Saitama | Japan | ||
63 | Sayama-shi | Saitama | Japan | ||
64 | Tokorozawa-shi | Saitama | Japan | ||
65 | Otsu-shi | Shiga | Japan | ||
66 | Utsunomiya-shi | Tochigi | Japan | ||
67 | Adachi-ku | Tokyo | Japan | ||
68 | Hachioji-shi | Tokyo | Japan | ||
69 | Koto-ku | Tokyo | Japan | ||
70 | Meguro-ku | Tokyo | Japan | ||
71 | Minato-ku | Tokyo | Japan | ||
72 | Shinjuku-ku | Tokyo | Japan | ||
73 | Tonami-shi | Toyama | Japan | ||
74 | Toyama-shi | Toyama | Japan | ||
75 | Iwakuni-shi | Yamaguchi | Japan | ||
76 | Shimonoseki-shi | Yamaguchi | Japan |
Sponsors and Collaborators
- Takeda
Investigators
- Study Director: Senior Manager, Takeda
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- TAK-438/CCT-302
- U1111-1123-8746
- JapicCTI-111610